In a Phase 2a study, ABBV-466, a dual-targeting therapy by AbbVie, achieved significantly higher endoscopic remission rates in Crohn's disease patients at Week 12 compared to anti-IL-23 p19 or anti-α4β7 monotherapies. The remission advantage increased further by Week 24, with gene analysis showing intestinal repair and tissue remodeling unique to ABBV-466. The study involved 300 patients with moderate to severe Crohn's disease, many of whom had failed prior advanced treatments, reflecting real-world complexity. Safety profiles were comparable across treatments. These results highlight ABBV-466's potential as a more effective treatment option and will be presented at the 2026 United European Gastroenterology Week Congress.
AbbVie's promising new therapy ABBV-466 for Crohn's disease adds to the company's innovative pipeline. On Pluang, AbbVie Inc (ABBV) shares trade at USD 285.00, near its 52-week high of USD 285.42, with a slight 0.15% decrease as of Oct 19, 2026 15:11 WIB. The stock's market cap stands at $504.37 billion, reflecting strong investor interest in its health sector advancements.
At the 2026 European Society for Medical Oncology (ESMO) Congress, AbbVie presented new and updated data on its oncology portfolio, including investigational drugs like Temab-A, ABBV-706, and ABBV-969. These drugs showed encouraging clinical activity...
AbbVie increased its quarterly dividend to $1.73, raising its annual payout by 5.5% despite a 29% stock price rise this year, which lowers the yield to about 2.4%. The company’s dividend payout ratio is around 49.5% of adjusted earnings, supported by...
AbbVie unveiled 20 new scientific presentations at the 2026 United European Gastroenterology Week, highlighting long-term and real-world data for its inflammatory bowel disease (IBD) treatments SKYRIZI (risankizumab) and RINVOQ (upadacitinib). The da...
